Clinical Impact Of Small TP53 Mutated Subclones In Chronic Lymphocytic Leukemia.
Rossi D, Khiabanian H, Ciardullo C et al.
Key Points:
TP53 mutations strong predictors of poor outcome and refractoriness in patients with CLL.
Study investigated frequency, evolution during disease course, and prognostic impact of small TP53 mutated subclones in newly diagnosed CLL.
309 newly diagnosed and previously untreated CLL patients analyzed for the study.
TP53 mutations (exons 4-8) screened on peripheral blood (PB) samples (tumor representation 70-98%) by amplicon-based deep-NGS.
Bioinformatic algorithm developed to cull TP53 variants out of background noise.
All subclonal mutations non-silent missed by Sanger sequencing and validated by AS-PCR.
Implications:
- TP53 mutated subclones detected by deep-NGS occur in significant fraction of newly diagnosed CLL and have unfavorable prognostic impact.
View the original abstract on the ASH website.
